The stock of Insmed Incorporated (NASDAQ:INSM) is a huge mover today! About 220,299 shares traded hands. Insmed Incorporated (NASDAQ:INSM) has declined 19.31% since April 4, 2016 and is downtrending. It has underperformed by 20.41% the S&P500.
The move comes after 5 months positive chart setup for the $688.15 million company. It was reported on Nov, 4 by Barchart.com. We have $16.67 PT which if reached, will make NASDAQ:INSM worth $337.19 million more.
Insmed Incorporated (NASDAQ:INSM) Ratings Coverage
Out of 6 analysts covering Insmed (NASDAQ:INSM), 4 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 67% are positive. Insmed has been the topic of 8 analyst reports since August 10, 2015 according to StockzIntelligence Inc. The firm has “Hold” rating by Zacks given on Thursday, August 20. The firm earned “Buy” rating on Friday, September 4 by Zacks. Stifel Nicolaus initiated Insmed Incorporated (NASDAQ:INSM) rating on Tuesday, March 15. Stifel Nicolaus has “Buy” rating and $23 price target. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Neutral” rating by Citigroup on Wednesday, March 16. The company was maintained on Tuesday, October 6 by H.C. Wainwright. The rating was downgraded by Zacks to “Hold” on Monday, August 10. The stock of Insmed Incorporated (NASDAQ:INSM) earned “Neutral” rating by UBS on Monday, November 9.
According to Zacks Investment Research, “Insmed is a biopharmaceutical company engaged in the development and commercialization of ARIKAYCE, or liposomal amikacin for inhalation, for at least two identified orphan patient populations: patients with nontuberculous mycobacteria (NTM) lung infections and cystic fibrosis (CF) patients with Pseudomonas aeruginosa lung infections. Insmed is also focused on the development of INS1009, the company’s inhaled treprostinil prodrug for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs.”
Insitutional Activity: The institutional sentiment increased to 1.65 in 2016 Q2. Its up 0.69, from 0.96 in 2016Q1. The ratio is positive, as 11 funds sold all Insmed Incorporated shares owned while 23 reduced positions. 17 funds bought stakes while 39 increased positions. They now own 55.48 million shares or 0.92% less from 56.00 million shares in 2016Q1.
Credit Suisse Ag last reported 0% of its portfolio in the stock. Los Angeles Cap Mngmt And Equity Rech reported 33,150 shares or 0% of all its holdings. Cubist Systematic Strategies Llc reported 28,238 shares or 0.02% of all its holdings. Tfs Capital Limited Liability Company has invested 0.03% of its portfolio in Insmed Incorporated (NASDAQ:INSM). Janus Cap Mngmt Ltd owns 2.85M shares or 0.02% of their US portfolio. Nationwide Fund Advisors holds 0% or 40,876 shares in its portfolio. Ubs Asset Management Americas Inc last reported 0% of its portfolio in the stock. Renaissance Techs Limited Liability Corp owns 149,300 shares or 0% of their US portfolio. Moreover, Earnest Limited Co has 0% invested in Insmed Incorporated (NASDAQ:INSM) for 1,130 shares. Alps has 0.01% invested in the company for 86,926 shares. The New York-based Bnp Paribas Arbitrage has invested 0% in Insmed Incorporated (NASDAQ:INSM). Blackrock Advsr Ltd Liability Corporation holds 0% or 29,932 shares in its portfolio. Blackrock Group Incorporated Limited holds 25,673 shares or 0% of its portfolio. California Pub Employees Retirement Systems owns 92,100 shares or 0% of their US portfolio. Point72 Asset Management Lp holds 0.01% or 201,354 shares in its portfolio.
More important recent Insmed Incorporated (NASDAQ:INSM) news were published by: Marketwatch.com which released: “Virtual Stock Exchange” on December 21, 2009, also Quotes.Wsj.com published article titled: “News Insmed Inc.INSM”, Fool.com published: “Why Insmed Incorporated Shares Skyrocketed” on June 18, 2014. More interesting news about Insmed Incorporated (NASDAQ:INSM) was released by: Globenewswire.com and their article: “EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action …” with publication date: August 12, 2016.
INSM Company Profile
Insmed Incorporated, incorporated on March 21, 2013, is a biopharmaceutical company. The Firm operates in the segment of development and commercialization of inhaled therapies for patients with serious lung diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.